1660. Dalbavancin Utilization Registry Investigating Value and Effectiveness (DRIVE): Outcomes Report on Real-World Use

BACKGROUND: Dalbavancin (dalba), a long-acting lipoglycopeptide approved by the US FDA and EMA for acute bacterial skin and skin structure infections (ABSSSI) has potent activity against Gram-positive pathogens including MRSA. We describe the real-world use of dalba in patients with ABSSSI, bloodstr...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Bruce M, Cleveland, Kerry O, Gonzalez, Pedro L, Rappo, Urania, Riccobene, Todd, Lyles, Rosie D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751683/
http://dx.doi.org/10.1093/ofid/ofac492.126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751683/
http://dx.doi.org/10.1093/ofid/ofac492.126

Ejemplares similares